Alaunos Therapeutics (TCRT) Debt to Equity (2016 - 2023)

Alaunos Therapeutics has reported Debt to Equity for 4 years, with the latest figure at $0.37 in Q1 2023.

• For the quarter ending Q1 2023, Debt to Equity fell 24.78% year-over-year to $0.37; the trailing twelve-month figure through Mar 2023 stood at $0.37 (down 24.78% YoY), and the FY2022 full-year result was $0.43, up 4.67% from the prior year.
• Debt to Equity for Q1 2023 stood at $0.37, down from $0.43 in the prior quarter.
• The five-year high for Debt to Equity was $0.71 in Q3 2022, with the low at $0.35 in Q3 2021.
• Historically, Debt to Equity has averaged $0.48 across 3 years, with a median of $0.43 in 2022.
• Annual changes were most pronounced in 2022 — Debt to Equity surged 100.32% — and 2023, when it decreased 24.78%.
• Alaunos Therapeutics' Debt to Equity stood at $0.42 in 2021, then rose by 4.67% to $0.43 in 2022, then retreated by 14.37% to $0.37 in 2023.
• The last three Debt to Equity figures came in at $0.37 (Q1 2023), $0.43 (Q4 2022), and $0.71 (Q3 2022), per Business Quant data.